Table 2

Characteristics among subjects with baseline biopsies (n=16)

	PD-L1 expression	TIL, PD-L1 expression	MSI markers present; mSINGS (↑ / ↓)	DNA-repair defect	Site of biopsy	Mutation load (#variants/Mbp sequenced)*	Neoepitope burden*
Responders
1	–	+	5/5 ↑	ATM R1618Q	LN	4428 (3.41)	113
2	–	–	0/5 ↓	Absent	Liver	352 (0.32)	24
3	–	–	0/5 ↓	Absent	Liver	210 (0.15)	7
Non-responders
1	NTD	–	1/5 ↓	Absent	Bone		–
2	NTD	–	0/5 ↓	Absent	Bone		–
3	NTD	–	0/5 ↓	Absent	LN	204 (0.43)	12
4	–	+	0/5 ↓	Absent	Bone	154 (0.37)	2
5	–	–	0/5 ↓	Absent	LN		–
6	–	–	0/5 ↓	Absent	LN	201 (0.24)	6
7	–	–	0/5 ↓	FANCC D195V	Bone		–
8	–	–	0/5 ↓	Absent	Bone		–
9	–	–	0/5 ↓	CHK2 I157T	Soft tissue	475 (0.50)	20
10	–	–	0/5 ↓	Absent	Bone		–
11	–	–	0/5 ↓	FANCA G1092Rfs*1116	Bone		–
12	–	–	0/5 ↓	Absent	LN	235 (0.32)	124
13	–	+	0/5 ↓	Absent	LN	167 (0.18)	8

*Subjects who had WES.
–, absent; +, present; LN, lymph node; MSI, microsatellite instability; NTD, no tumor detected; PD-L1, programmed death-ligand 1; TIL, tumor-infiltrating lymphocyte; WES, whole exome sequencing.